224 related articles for article (PubMed ID: 9192661)
1. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity.
Armstrong TD; Clements VK; Martin BK; Ting JP; Ostrand-Rosenberg S
Proc Natl Acad Sci U S A; 1997 Jun; 94(13):6886-91. PubMed ID: 9192661
[TBL] [Abstract][Full Text] [Related]
2. MHC class II and CD80 tumor cell-based vaccines are potent activators of type 1 CD4+ T lymphocytes provided they do not coexpress invariant chain.
Ilkovitch D; Ostrand-Rosenberg S
Cancer Immunol Immunother; 2004 Jun; 53(6):525-32. PubMed ID: 14730400
[TBL] [Abstract][Full Text] [Related]
3. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunol; 1998 Jan; 160(2):661-6. PubMed ID: 9551900
[TBL] [Abstract][Full Text] [Related]
4. Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain.
Thompson JA; Dissanayake SK; Ksander BR; Knutson KL; Disis ML; Ostrand-Rosenberg S
Cancer Res; 2006 Jan; 66(2):1147-54. PubMed ID: 16424052
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells.
Qiu G; Goodchild J; Humphreys RE; Xu M
Cancer Immunol Immunother; 1999 Dec; 48(9):499-506. PubMed ID: 10602887
[TBL] [Abstract][Full Text] [Related]
6. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
7. Major histocompatibility complex class II+ invariant chain negative breast cancer cells present unique peptides that activate tumor-specific T cells from breast cancer patients.
Chornoguz O; Gapeev A; O'Neill MC; Ostrand-Rosenberg S
Mol Cell Proteomics; 2012 Nov; 11(11):1457-67. PubMed ID: 22942358
[TBL] [Abstract][Full Text] [Related]
8. Class II-transfected tumor cells directly present endogenous antigen to CD4+ T cells in vitro and are APCs for tumor-encoded antigens in vivo.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunother; 1998 May; 21(3):218-24. PubMed ID: 9610914
[TBL] [Abstract][Full Text] [Related]
9. Invariant chain and the MHC class II cytoplasmic domains regulate localization of MHC class II molecules to lipid rafts in tumor cell-based vaccines.
Dolan BP; Phelan TP; Ilkovitch D; Qi L; Wade WF; Laufer TM; Ostrand-Rosenberg S
J Immunol; 2004 Jan; 172(2):907-14. PubMed ID: 14707062
[TBL] [Abstract][Full Text] [Related]
10. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice.
Baskar S; Glimcher L; Nabavi N; Jones RT; Ostrand-Rosenberg S
J Exp Med; 1995 Feb; 181(2):619-29. PubMed ID: 7836917
[TBL] [Abstract][Full Text] [Related]
11. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.
Dissanayake SK; Thompson JA; Bosch JJ; Clements VK; Chen PW; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2004 Mar; 64(5):1867-74. PubMed ID: 14996751
[TBL] [Abstract][Full Text] [Related]
12. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules.
Baskar S; Ostrand-Rosenberg S; Nabavi N; Nadler LM; Freeman GJ; Glimcher LH
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5687-90. PubMed ID: 7685909
[TBL] [Abstract][Full Text] [Related]
13. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
[TBL] [Abstract][Full Text] [Related]
14. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes.
Ostrand-Rosenberg S; Roby C; Clements VK; Cole GA
Int J Cancer Suppl; 1991; 6():61-8. PubMed ID: 1906055
[TBL] [Abstract][Full Text] [Related]
15. Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide.
Ladányi A; Nishimura MI; Rosenberg SA; Yang JC
J Immunother; 2000 Jan; 23(1):36-47. PubMed ID: 10687136
[TBL] [Abstract][Full Text] [Related]
16. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice.
Baskar S; Azarenko V; Garcia Marshall E; Hughes E; Ostrand-Rosenberg S
Cell Immunol; 1994 Apr; 155(1):123-33. PubMed ID: 8168141
[TBL] [Abstract][Full Text] [Related]
17. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity.
Wang RF
Trends Immunol; 2001 May; 22(5):269-76. PubMed ID: 11323286
[TBL] [Abstract][Full Text] [Related]
18. Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes.
Chen PW; Ullrich SE; Ananthaswamy HN
J Leukoc Biol; 1994 Oct; 56(4):469-74. PubMed ID: 7930943
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
20. Tumor cells expressing major histocompatibility complex class II and B7 activation molecules stimulate potent tumor-specific immunity.
Baskar S; Nabavi N; Glimcher LH; Ostrand-Rosenberg S
J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):209-15. PubMed ID: 8297902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
